Cerevel Therapeutics Holdings (CERE) Prices 14M Share Offering at $25/sh
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/11/2026
- Wall St set to gain on tech rebound, Middle East in focus
- SpaceX prices historic IPO at $135/share in largest ever new listing
- Oil drops as Trump cancels planned strikes against Iran
- Intel rallies as BofA double-upgrades stock on increased CPU, foundry visibility
- Oppenheimer sees little strategic case for Tesla-SpaceX merger
- NASDAQ adds five companies to NASDAQ-100 index in quarterly rebalance
- Needham Starts Hyliion Holdings (HYLN) at Buy
- Adobe CFO Dan Durn to depart company in June 2026
- Oppenheimer Starts SpaceX (SPCX) at Outperform, PT $190, 'space infrastructure appears structurally advantaged'
- Pentagon reportedly locked down, hazmat teams responding
Cerevel Therapeutics Holdings (CERE) Cerevel Therapeutics Holdings (NASDAQ: CERE) 30-day option implied volatility at 143 on more puts than calls
July 2, 2021 4:42 AM EDTCerevel Therapeutics Holdings (NASDAQ: CERE) 30-day option implied volatility is at 143; compared to its 52-week range of 83 to 345. Call put ratio 1 call to 2 puts.
... MoreCerevel Therapeutics Holdings (CERE) call put ratio 1 call to 2 puts after sharp rally
July 1, 2021 3:55 PM EDTCerevel Therapeutics Holdings (NASDAQ: CERE) 30-day option implied volatility is at 140; compared to its 52-week range of 83 to 345. Call put ratio 1 call to 2 puts.
... MorePre-Open Stock Movers 06/30: (OCUP) (ASTS) (XELA) Higher; (ALT) (ECOR) (REPX) Lower (more...)
June 30, 2021 9:27 AM EDTPre-Open Stock Movers:
Ocuphire Pharma, Inc. (Nasdaq: OCUP) 40.6% HIGHER; announced that the VEGA-1 Phase 2 clinical trial evaluating the efficacy and safety of Nyxol in combination with low-dose pilocarpine (LDP) in presbyopic subjects successfully met its primary and many secondary endpoints. On the strength of these results, Ocuphire plans to move into Phase 3. Given the rapid onset and sustained duration of efficacy, the favorable safety profile, and the potential tunability of... More
Cerevel Therapeutics (CERE) PT Raised to $30 at Goldman Sachs
June 30, 2021 9:13 AM EDTGoldman Sachs analyst Graig Suvannavejh raised the price target on Cerevel Therapeutics (NASDAQ: CERE) to $30.00 (from $23.00) while maintaining a Buy rating.... More
